Suxibuzone
Suxibuzone is a prodrug of phenylbutazone, a pyrazolidine-class NSAID, which is hydrolyzed in the body to the active metabolite phenylbutazone and ketobutazone, used for anti-inflammatory and analgesic treatment of musculoskeletal conditions and arthritis. The prodrug form was developed to reduce the gastrointestinal irritation associated with phenylbutazone by providing slower release of the active drug. Like phenylbutazone, it inhibits cyclooxygenase enzymes and has additional effects on leukocyte migration.
Molecular Weight
438.5000 g/mol
LogP
3.60
TPSA
104.00 Ų
Lipinski RO5
Pass
Mechanism of Action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Structure
Cite this structure
Embed this structure
SMILES
CCCCC1(COC(=O)CCC(=O)O)C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
InChI
InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)
Molecular Formula
C24H26N2O6
HBD / HBA
1 / 6
Rotatable Bonds
11
Heavy Atoms
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Suxibuzone is a prodrug of phenylbutazone, a pyrazolidine-class NSAID, which is hydrolyzed in the body to the active metabolite phenylbutazone and ketobutazone, used for anti-inflammatory and analgesic treatment of musculoskeletal conditions and arthritis. The prodrug form was developed to reduce the gastrointestinal irritation associated with phenylbutazone by providing slower release of the active drug. Like phenylbutazone, it inhibits cyclooxygenase enzymes and has additional effects on leukocyte migration.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Suxibuzone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1414320. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5362. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="suxibuzone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/suxibuzone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/suxibuzone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/suxibuzone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="suxibuzone"></drugfyi-drug>